Merck's RSV antibody Clesrovimab for infants shows 60.4% effectiveness in mid-to-late stage clinical trial MD Bureau19 Oct 2024 12:15 PM ISTThe drug clesrovimab also helped reduce RSV associated hospitalizations by 84.2% compared to placebo, Merck said.
Sanofi gets CDSCO marketing nod for RSV treatment Beyfortus in India Ruchika Sharma1 Aug 2024 5:30 PM ISTDrugmaker, Sanofi India, has received marketing authorisation approval from the Central Drugs Standard Control Organisation (CDSCO) for Beyfortus in...
Nirsevimab use may reduce infant hospitalizations due to RSV by 82 percent: Lancet Dr. Kamal Kant Kohli3 May 2024 7:00 PM ISTNirsevimab use may reduce infant hospitalizations due to respiratory syncytial virus (RSV) by 82 percent, shows real world evidence published in The...
AstraZeneca-Sanofi Beyfortus approved in Japan for prevention of RSV disease in infants Ruchika Sharma31 March 2024 12:30 PM ISTCambridge: AstraZeneca and Sanofi's Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of...
AstraZeneca-Sanofi Beyfortus gets nod for RSV disease prevention in infants in China Ruchika Sharma2 Jan 2024 3:06 PM ISTChina: AstraZeneca and Sanofi's Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of...
Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline Ruchika Sharma8 Dec 2023 1:30 PM ISTNew Delhi: Sanofi said on Thursday it will focus on 12 potential blockbuster drug candidates and prioritise development in immunology, as it...
Sanofi-AstraZeneca Beyfortus gets unanimous US CDC Advisory Committee recommendation to prevent RSV in neonates, infants Ruchika Sharma4 Aug 2023 1:09 PM ISTParis: Sanofi has recently announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization...
FDA approves new drug to Prevent RSV in infants and very young children Dr. Kamal Kant Kohli19 July 2023 11:45 AM ISTThe U.S. Food and Drug Administration has approved The FDA approved nirsevimab (Beyfortus) for prevention of respiratory syncytial virus (RSV)-related...
Sanofi-AstraZeneca Beyfortus gets USFDA nod for protection of infants against RSV disease Ruchika Sharma18 July 2023 11:24 AM ISTParis: The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of...
AstraZeneca, Sanofi, Sobi simplify contractual agreements for Nirsevimab Ruchika Sharma12 April 2023 3:44 PM ISTBeyfortus (nirsevimab), an investigational long-acting antibody designed to protect all infants against RSV infections from birth through their first...
Sanofi gets European Commission nod for Beyfortus to prevent RSV disease in infants Ruchika Sharma5 Nov 2022 3:00 PM ISTRSV is the most common cause of LRTI, including bronchiolitis and pneumonia, in infants.
EMA Committee recommends nod of Sanofi, AstraZeneca Beyfortus for prevention of RSV disease in infants Ruchika Sharma18 Sept 2022 3:00 PM ISTParis: Sanofi and AstraZeneca have recently announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has...
